Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYR-101 in Schizophrenia
NCT00861796Phase 2Completed
- Sponsor
- Minerva Therapeutics
- Start
- Mar 2008
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of roluperidone in schizophrenia, sponsored by Minerva Therapeutics. Started Mar 2008; status: completed.
02
Drugs
roluperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00861796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00861796.